FDA Approves First Ophthalmic Bevacizumab; Outlook Therapeutics Eyes Year-End Launch
OTLK has more than doubled off its 52-week low of $0.161 on elevated volume (2.8× avg).
Summary
The FDA approved LYTENAVA for wet AMD, making it the first and only approved ophthalmic bevacizumab. Shares swung widely, hitting an intraday high of $1.75 before closing up 6% at $1.41. The company expects the drug to be available to patients before year end and anticipates 12 years of market exclusivity. This follows the earlier Reuters report of the approval, adding commercial launch timing and specific price action. The approval transforms Outlook from a pre-revenue biotech to a commercial-stage company with a first-mover advantage in a large market.
At the time of this announcement, OTLK was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.7M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.